193 related articles for article (PubMed ID: 9457310)
1. Serum levels of soluble interleukin-2 receptor in renal cell carcinoma.
Matsumoto T; Furukawa A; Sumiyoshi Y; Akiyama KY; Kanayama HO; Kagawa S
Urology; 1998 Jan; 51(1):145-9. PubMed ID: 9457310
[TBL] [Abstract][Full Text] [Related]
2. [The role of serum soluble interleukin 2 receptor (sIL-2R) levels in patients with renal cell carcinoma].
Akiyama K; Tsuji M; Kurokawa Y; Yokota K; Kojima K; Naruo S; Kanayana HO; Kagawa S
Nihon Hinyokika Gakkai Zasshi; 1997 Apr; 88(4):473-8. PubMed ID: 9155114
[TBL] [Abstract][Full Text] [Related]
3. [Serum soluble interleukin-2 receptor levels in patients with renal cell carcinoma: a comparison of values before and after surgery].
Tsukamoto S; Ishikawa S; Yamauchi A; Saitou S
Hinyokika Kiyo; 2000 Oct; 46(10):695-9. PubMed ID: 11215193
[TBL] [Abstract][Full Text] [Related]
4. Soluble immunological parameters and early prognosis of renal cell cancer patients.
Kallio JP; Tammela TL; Marttinen AT; Kellokumpu-Lehtinen PL
J Exp Clin Cancer Res; 2001 Dec; 20(4):523-8. PubMed ID: 11876546
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
[TBL] [Abstract][Full Text] [Related]
6. Increased serum level of soluble interleukin-2 receptor is associated with a worse response of metastatic clear cell renal cell carcinoma to interferon alpha and sequential VEGF-targeting therapy.
Nukui A; Masuda A; Abe H; Arai K; Yoshida KI; Kamai T
BMC Cancer; 2017 May; 17(1):372. PubMed ID: 28545581
[TBL] [Abstract][Full Text] [Related]
7. Renal cell carcinoma-associated immune impairment that may interfere with the response to cytokine therapy.
Lauerová L; Dusek L; Simícková M; Rovný F; Spurný V; Rovný A; Slampa P; Zaloudík J; Rejthar A; Wotke J; Kovarík J
Neoplasma; 1999; 46(3):141-9. PubMed ID: 10613588
[TBL] [Abstract][Full Text] [Related]
8. [Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma].
Shimomura Y; Tsurumi H; Sawada M; Yamada T; Hara T; Fukuno K; Goto H; Moriwaki H
Rinsho Ketsueki; 1999 Aug; 40(8):639-45. PubMed ID: 10496038
[TBL] [Abstract][Full Text] [Related]
9. Soluble interleukin-2 receptor in stage I-III melanoma.
Ottaiano A; Leonardi E; Simeone E; Ascierto PA; Scala S; Calemma R; Bryce J; Caracò C; Satriano RA; Gianfranco N; Franco R; Botti G; Castello G
Cytokine; 2006 Feb; 33(3):150-5. PubMed ID: 16517174
[TBL] [Abstract][Full Text] [Related]
10. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
Hurteau JA; Woolas RP; Jacobs IJ; Oram DC; Kurman CC; Rubin LA; Nelson DL; Berchuck A; Bast RC; Mills GB
Cancer; 1995 Nov; 76(9):1615-20. PubMed ID: 8635066
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6, soluble interleukin-2 receptor and soluble interleukin-6 receptor in the sera of patients with different histological patterns of rheumatoid synovitis.
Klimiuk PA; Sierakowski S; Latosiewicz R; Cylwik JP; Cylwik B; Skowronski J; Chwiecko J
Clin Exp Rheumatol; 2003; 21(1):63-9. PubMed ID: 12673891
[TBL] [Abstract][Full Text] [Related]
12. Serum soluble interleukin 2 (IL-2) receptor (sIL-2R) in differentiated thyroid carcinoma.
Mariotti S; Barbesino G; Caturegli P; Marinò M; Manetti L; Fugazzola L; Pacini F; Pinchera A
J Endocrinol Invest; 1994 Dec; 17(11):861-7. PubMed ID: 7745234
[TBL] [Abstract][Full Text] [Related]
13. [Usefulness of the measurement of serum soluble IL-2 receptor alpha chain levels in clinical monitoring of non-Hodgkin lymphoma].
Setoyama Y; Imai J; Ishikawa T; Sakaida H; Takaori-Kondo A; Kawamata S; Uchiyama T
Rinsho Byori; 1994 Aug; 42(8):834-42. PubMed ID: 7933620
[TBL] [Abstract][Full Text] [Related]
14. [Value of serum soluble interleukin-2R, interleukin-6 and C-reactive protein in the early diagnosis of Kawasaki disease].
Peng Q; Wu Q; Chen CH; Hong H; Zhang LY
Zhongguo Dang Dai Er Ke Za Zhi; 2006 Jun; 8(3):208-10. PubMed ID: 16787593
[TBL] [Abstract][Full Text] [Related]
15. Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus.
Doganay S; Evereklioglu C; Er H; Türköz Y; Sevinç A; Mehmet N; Savli H
Eye (Lond); 2002 Mar; 16(2):163-70. PubMed ID: 11988817
[TBL] [Abstract][Full Text] [Related]
16. Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation.
Grutters JC; Fellrath JM; Mulder L; Janssen R; van den Bosch JM; van Velzen-Blad H
Chest; 2003 Jul; 124(1):186-95. PubMed ID: 12853522
[TBL] [Abstract][Full Text] [Related]
17. Serum soluble interleukin-2 receptor level as a prognostic indicator in gastric cancer.
Nakata B; Chung KH; Kato Y; Yamashita Y; Inui A; Arimoto Y; Maeda K; Onoda N; Sawada T; Sowa M
Br J Cancer; 1998 Jun; 77(11):1820-4. PubMed ID: 9667652
[TBL] [Abstract][Full Text] [Related]
18. Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2.
Gooding R; Riches P; Dadian G; Moore J; Gore M
Br J Cancer; 1995 Aug; 72(2):452-5. PubMed ID: 7640231
[TBL] [Abstract][Full Text] [Related]
19. Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications.
Viviani S; Camerini E; Bonfante V; Santoro A; Balzarotti M; Fornier M; Devizzi L; Verderio P; Valagussa P; Bonadonna G
Br J Cancer; 1998 Mar; 77(6):992-7. PubMed ID: 9528846
[TBL] [Abstract][Full Text] [Related]
20. High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma.
Wang L; Wang JH; Liu WJ; Wang WD; Wang H; Chen XQ; Geng QR; Lu Y; Xia ZJ
Ann Hematol; 2017 Dec; 96(12):2079-2088. PubMed ID: 28871325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]